Myosin XVIIIa inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of Myosin XVIIIa, a member of the unconventional myosin family of motor proteins. Myosin XVIIIa is distinct from other myosins due to its unique structure, which includes a motor domain, a coiled-coil domain, and a PDZ-binding motif, allowing it to interact with various cellular components beyond its traditional role in actin-based motility. Myosin XVIIIa is involved in a wide range of cellular processes, including the regulation of cytoskeletal dynamics, cell adhesion, and intracellular transport. It plays a crucial role in maintaining cellular architecture by linking the actin cytoskeleton to membrane-associated complexes, influencing the organization of the extracellular matrix, and participating in signal transduction pathways. By inhibiting Myosin XVIIIa, researchers can disrupt these critical interactions and functions, providing a tool to study the specific roles of this protein in cellular mechanics and signaling.
In research settings, Myosin XVIIIa inhibitors are valuable tools for exploring the diverse functions of Myosin XVIIIa in cellular biology. By blocking Myosin XVIIIa activity, scientists can investigate how the inhibition affects cytoskeletal organization, cell adhesion properties, and the mechanical stability of cells. This inhibition also allows researchers to examine the role of Myosin XVIIIa in processes such as cell migration, tissue morphogenesis, and the coordination of cellular responses to external stimuli. Additionally, Myosin XVIIIa inhibitors provide insights into the interactions between this motor protein and other components of the cellular machinery, such as actin filaments, integrins, and signaling molecules, revealing the complex networks that regulate cellular structure and function. Through these studies, the use of Myosin XVIIIa inhibitors enhances our understanding of the molecular mechanisms underlying cell motility, adhesion, and signaling, and the broader implications of these processes in maintaining cellular integrity and coordinating responses to the cellular environment.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
H-1152 dihydrochloride | 451462-58-1 | sc-203592 sc-203592A | 1 mg 5 mg | $104.00 $364.00 | 7 | |
Another ROCK inhibitor that indirectly inhibits MYO18A activity by targeting a downstream effector. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor that can affect MYO18A activity by modulating signaling pathways that control cytoskeletal organization. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Similar to LY294002, Wortmannin is a PI3K inhibitor affecting pathways related to MYO18A. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
Inhibits myosin light chain kinase, which can indirectly affect MYO18A by influencing myosin-based cellular functions. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
A microtubule-depolymerizing agent that can indirectly affect MYO18A's role in intracellular trafficking and cell motility. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Stabilizes microtubules, potentially affecting MYO18A’s interaction with microtubules and therefore its cellular functions. | ||||||